Propranolol in the treatment of upper airway hemangiomas

Lauren C.Anderson de Moreno, Bruce H. Matt, Gregory Montgomery, Young Jee Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Airway hemangiomas (AHs), which are common in infant airways, often cause significant upper airway obstruction. The various therapies used for AH have limitations and complications. Propranolol may have a potential role in its treatment, since it leads to regression or stabilization of cutaneous infantile hemangiomas. To date, only 4 previous case reports (7 patients) in which propranolol was used for AH have been published. Based on encouraging preliminary data on propranolol use for AH treatment, our goal was to further investigate propranolol as an effective initial treatment of upper AHs that cause significant obstruction symptoms. In this retrospective case series, we reviewed the medical records of 5 consecutive pediatric patients with AH (glottic and subglottic) treated with propranolol at a tertiary care children's hospital. All 5 patients were 2 months of age at the time of hemangioma diagnosis and had stridor and physical signs of severe upper airway obstruction. Hemangioma was diagnosed by flexible laryngoscopy or flexible bronchoscopy. All patients received propranolol 2 mg/kg/day and showed significant relief of obstruction symptoms within 24 hours of treatment initiation. All patients tolerated propranolol without significant cardiovascular complications. Outcomes from this case series, in conjunction with available case reports in the literature, suggest that propranolol is a safe initial treatment for symptomatic upper AH.

Original languageEnglish (US)
Pages (from-to)209-214
Number of pages6
JournalEar, Nose and Throat Journal
Volume92
Issue number4
StatePublished - Jun 4 2013

Fingerprint

Hemangioma
Propranolol
Therapeutics
Airway Obstruction
Laryngoscopy
Respiratory Sounds
Bronchoscopy
Tertiary Healthcare
Tongue
Medical Records
Pediatrics
Skin

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Propranolol in the treatment of upper airway hemangiomas. / de Moreno, Lauren C.Anderson; Matt, Bruce H.; Montgomery, Gregory; Kim, Young Jee.

In: Ear, Nose and Throat Journal, Vol. 92, No. 4, 04.06.2013, p. 209-214.

Research output: Contribution to journalArticle

de Moreno, Lauren C.Anderson ; Matt, Bruce H. ; Montgomery, Gregory ; Kim, Young Jee. / Propranolol in the treatment of upper airway hemangiomas. In: Ear, Nose and Throat Journal. 2013 ; Vol. 92, No. 4. pp. 209-214.
@article{c9780fee3c7a49d8a3f47961247056ce,
title = "Propranolol in the treatment of upper airway hemangiomas",
abstract = "Airway hemangiomas (AHs), which are common in infant airways, often cause significant upper airway obstruction. The various therapies used for AH have limitations and complications. Propranolol may have a potential role in its treatment, since it leads to regression or stabilization of cutaneous infantile hemangiomas. To date, only 4 previous case reports (7 patients) in which propranolol was used for AH have been published. Based on encouraging preliminary data on propranolol use for AH treatment, our goal was to further investigate propranolol as an effective initial treatment of upper AHs that cause significant obstruction symptoms. In this retrospective case series, we reviewed the medical records of 5 consecutive pediatric patients with AH (glottic and subglottic) treated with propranolol at a tertiary care children's hospital. All 5 patients were 2 months of age at the time of hemangioma diagnosis and had stridor and physical signs of severe upper airway obstruction. Hemangioma was diagnosed by flexible laryngoscopy or flexible bronchoscopy. All patients received propranolol 2 mg/kg/day and showed significant relief of obstruction symptoms within 24 hours of treatment initiation. All patients tolerated propranolol without significant cardiovascular complications. Outcomes from this case series, in conjunction with available case reports in the literature, suggest that propranolol is a safe initial treatment for symptomatic upper AH.",
author = "{de Moreno}, {Lauren C.Anderson} and Matt, {Bruce H.} and Gregory Montgomery and Kim, {Young Jee}",
year = "2013",
month = "6",
day = "4",
language = "English (US)",
volume = "92",
pages = "209--214",
journal = "Ear, Nose and Throat Journal",
issn = "0145-5613",
publisher = "Medquest Communications LLC",
number = "4",

}

TY - JOUR

T1 - Propranolol in the treatment of upper airway hemangiomas

AU - de Moreno, Lauren C.Anderson

AU - Matt, Bruce H.

AU - Montgomery, Gregory

AU - Kim, Young Jee

PY - 2013/6/4

Y1 - 2013/6/4

N2 - Airway hemangiomas (AHs), which are common in infant airways, often cause significant upper airway obstruction. The various therapies used for AH have limitations and complications. Propranolol may have a potential role in its treatment, since it leads to regression or stabilization of cutaneous infantile hemangiomas. To date, only 4 previous case reports (7 patients) in which propranolol was used for AH have been published. Based on encouraging preliminary data on propranolol use for AH treatment, our goal was to further investigate propranolol as an effective initial treatment of upper AHs that cause significant obstruction symptoms. In this retrospective case series, we reviewed the medical records of 5 consecutive pediatric patients with AH (glottic and subglottic) treated with propranolol at a tertiary care children's hospital. All 5 patients were 2 months of age at the time of hemangioma diagnosis and had stridor and physical signs of severe upper airway obstruction. Hemangioma was diagnosed by flexible laryngoscopy or flexible bronchoscopy. All patients received propranolol 2 mg/kg/day and showed significant relief of obstruction symptoms within 24 hours of treatment initiation. All patients tolerated propranolol without significant cardiovascular complications. Outcomes from this case series, in conjunction with available case reports in the literature, suggest that propranolol is a safe initial treatment for symptomatic upper AH.

AB - Airway hemangiomas (AHs), which are common in infant airways, often cause significant upper airway obstruction. The various therapies used for AH have limitations and complications. Propranolol may have a potential role in its treatment, since it leads to regression or stabilization of cutaneous infantile hemangiomas. To date, only 4 previous case reports (7 patients) in which propranolol was used for AH have been published. Based on encouraging preliminary data on propranolol use for AH treatment, our goal was to further investigate propranolol as an effective initial treatment of upper AHs that cause significant obstruction symptoms. In this retrospective case series, we reviewed the medical records of 5 consecutive pediatric patients with AH (glottic and subglottic) treated with propranolol at a tertiary care children's hospital. All 5 patients were 2 months of age at the time of hemangioma diagnosis and had stridor and physical signs of severe upper airway obstruction. Hemangioma was diagnosed by flexible laryngoscopy or flexible bronchoscopy. All patients received propranolol 2 mg/kg/day and showed significant relief of obstruction symptoms within 24 hours of treatment initiation. All patients tolerated propranolol without significant cardiovascular complications. Outcomes from this case series, in conjunction with available case reports in the literature, suggest that propranolol is a safe initial treatment for symptomatic upper AH.

UR - http://www.scopus.com/inward/record.url?scp=84878376446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878376446&partnerID=8YFLogxK

M3 - Article

C2 - 23599104

AN - SCOPUS:84878376446

VL - 92

SP - 209

EP - 214

JO - Ear, Nose and Throat Journal

JF - Ear, Nose and Throat Journal

SN - 0145-5613

IS - 4

ER -